Moreover, TRAIL-R1 and TRAIL-R2 both are able to activate NF-κB (Schneider et al, 1997) and inhibition of NF-κB augmented TRAIL-mediated apoptosis in haematopoietic (Jeremias et al, 1998) and pancreatic carcinoma cells (Trauzold et al, 2001). Here, TNFRSF10A is linked to exocrine pancreatic carcinoma.